Healthcare and economic burden of anticholinergic use in adults with overactive bladder: a systematic literature review

J Comp Eff Res. 2022 Dec;11(18):1375-1394. doi: 10.2217/cer-2022-0160. Epub 2022 Nov 10.

Abstract

Aim: To determine the economic burden associated with anticholinergic medication use in adults with overactive bladder (OAB) in the USA. Methods: A systematic literature review was conducted to identify articles assessing healthcare resource utilization (HCRU) and costs associated with anticholinergic use in adults with OAB. Results: From the 34 articles identified, increased anticholinergic burden, switching anticholinergic treatments and potentially inappropriate anticholinergic use were associated with increased HCRU and/or costs. However, studies comparing patients with OAB receiving anticholinergics to individuals with untreated OAB or without OAB reported a mix of increases and decreases in HCRU and costs. Conclusion: Additional controlled studies assessing the economic impact of anticholinergics in OAB are needed and may enable optimization of economic and potentially patient outcomes.

Keywords: HCRU; anticholinergic; anticholinergic burden; antimuscarinic; economic burden; healthcare costs; healthcare resource utilization; incontinence; overactive bladder; urology.

Publication types

  • Systematic Review
  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Cholinergic Antagonists / therapeutic use
  • Costs and Cost Analysis
  • Financial Stress
  • Humans
  • Patient Acceptance of Health Care
  • Urinary Bladder, Overactive* / drug therapy

Substances

  • Cholinergic Antagonists